TY - CHAP
T1 - Role of the raphe-serotonin system in Parkinson's disease
T2 - Compensatory versus maladaptive plasticity
AU - Galfano, Ashley
AU - Tseng, Kuei
AU - Manfredsson, Fredric
AU - Bishop, Christopher
N1 - Publisher Copyright: © 2026 Elsevier B.V.
PY - 2026
Y1 - 2026
N2 - Parkinson's Disease (PD) is routinely treated with levodopa ( l -DOPA). Chronic use can lead to the development of l -DOPA induced dyskinesia (LID), an additional motor impairment which diminishes patient quality of life. There is a complex interplay between the dopamine and serotonin systems in both the progression of PD and LID. Neuroanatomical and functional modifications occur, driving many of the motor, cognitive, and affective disorders that accompany the disease. Here, we focus on the neuroplasticity of the serotonin system and how compensation can turn maladaptive, potentiating the negative effects of l -DOPA treatment. While a significant amount of literature supports the role of serotonergic neurons in LID, its role in non-motor symptoms is underdeveloped and we recognize key questions which remain that can lead to optimized therapeutic strategies for patients.
AB - Parkinson's Disease (PD) is routinely treated with levodopa ( l -DOPA). Chronic use can lead to the development of l -DOPA induced dyskinesia (LID), an additional motor impairment which diminishes patient quality of life. There is a complex interplay between the dopamine and serotonin systems in both the progression of PD and LID. Neuroanatomical and functional modifications occur, driving many of the motor, cognitive, and affective disorders that accompany the disease. Here, we focus on the neuroplasticity of the serotonin system and how compensation can turn maladaptive, potentiating the negative effects of l -DOPA treatment. While a significant amount of literature supports the role of serotonergic neurons in LID, its role in non-motor symptoms is underdeveloped and we recognize key questions which remain that can lead to optimized therapeutic strategies for patients.
KW - Dopamine
KW - Dopamine transporter
KW - Parkinson's disease
KW - Raphe nuclei
KW - Serotonin
KW - Serotonin transporter
KW - l-DOPA induced dyskinesia
UR - https://www.scopus.com/pages/publications/105021243775
U2 - 10.1016/B978-0-443-21992-4.00009-9
DO - 10.1016/B978-0-443-21992-4.00009-9
M3 - Chapter
T3 - Handbook of Behavioral Neuroscience
SP - 287
EP - 298
BT - Handbook of Behavioral Neuroscience
PB - Elsevier B.V.
ER -